Citations (92)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Abhinav Kumar, John P J Rocke & B Nirmal Kumar. (2020) Evolving treatments in high-risk neuroblastoma. Expert Opinion on Orphan Drugs 8:12, pages 497-506.
Read now
Read now
Michelle E Keyel & C Patrick Reynolds. (2019) Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy 13, pages 1-12.
Read now
Read now
Concetta Quintarelli, Domenico Orlando, Iolanda Boffa, Marika Guercio, Vinicia Assunta Polito, Andrea Petretto, Chiara Lavarello, Matilde Sinibaldi, Gerrit Weber, Francesca Del Bufalo, Ezio Giorda, Marco Scarsella, Stefania Petrini, Daria Pagliara, Franco Locatelli, Biagio De Angelis & Ignazio Caruana. (2018) Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. OncoImmunology 7:6.
Read now
Read now
Nikolai Siebert, Christian Jensen, Sascha Troschke-Meurer, Maxi Zumpe, Madlen Jüttner, Karoline Ehlert, Silke Kietz, Ina Müller & Holger N. Lode. (2016) Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. OncoImmunology 5:11.
Read now
Read now
Nikolai Siebert, Christin Eger, Diana Seidel, Madlen Jüttner, Maxi Zumpe, Danilo Wegner, Silke Kietz, Karoline Ehlert, Gareth J. Veal, Werner Siegmund, Michael Weiss, Hans Loibner, Ruth Ladenstein & Holger N. Lode. (2016) Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. mAbs 8:3, pages 604-616.
Read now
Read now
Garrett M Brodeur, Radhika Iyer, Jamie L Croucher, Tiangang Zhuang, Mayumi Higashi & Venkatadri Kolla. (2014) Therapeutic targets for neuroblastomas. Expert Opinion on Therapeutic Targets 18:3, pages 277-292.
Read now
Read now
Weili Sun & Shakeel Modak. (2012) Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. OncoTargets and Therapy 5, pages 21-29.
Read now
Read now
Byram W Bridle. (2011) Neuroendocrine cancer vaccines in clinical trials. Expert Review of Vaccines 10:6, pages 811-823.
Read now
Read now
Rani E George, Lisa Diller & Mark L Bernstein. (2010) Pharmacotherapy of neuroblastoma. Expert Opinion on Pharmacotherapy 11:9, pages 1467-1478.
Read now
Read now
Christian M Capitini, Crystal L Mackall & Alan S Wayne. (2010) Immune-based therapeutics for pediatric cancer. Expert Opinion on Biological Therapy 10:2, pages 163-178.
Read now
Read now
Articles from other publishers (82)
Yasuyuki Matsumoto & Tongzhong Ju. (2023) Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors. Cancers 15:14, pages 3536.
Crossref
Crossref
Amalia Varo, Alicia Castañeda, Saray Chamorro, Juan Pablo Muñoz, Maite Gorostegui, Mónica S. Celma, Sandra Lopez, Margarida Simao, Sara Perez-Jaume & Jaume Mora. (2023) Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab. Frontiers in Oncology 13.
Crossref
Crossref
Werner Krause. (2023) mRNA—From COVID-19 Treatment to Cancer Immunotherapy. Biomedicines 11:2, pages 308.
Crossref
Crossref
Jennifer Cabral, Erica I. Fernandez, Bonnie Toy & Rita Secola. (2022) Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma. Pediatric Drugs 25:1, pages 13-25.
Crossref
Crossref
Tanvir Ahmed. (2022) Immunotherapy for neuroblastoma using mRNA vaccines. Advances in Cancer Biology - Metastasis 4, pages 100033.
Crossref
Crossref
Jaume Mora, Alicia Castañeda, Maite Gorostegui, Vicente Santa‐María, Moira Garraus, Juan Pablo Muñoz, Amalia Varo, Sara Perez‐Jaume & Salvador Mañe. (2021) Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission. Pediatric Blood & Cancer 68:10.
Crossref
Crossref
Jaume Mora, Alicia Castañeda, Maria Colombo, Maite Gorostegui, Fernando Gomez, Salvador Mañe, Vicente Santa-Maria, Moira Garraus, Napoleon Macias, Sara Perez-Jaume, Oscar Muñoz, Juan Muñoz, Ignasi Barber & Mariona Suñol. (2021) Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers 13:6, pages 1264.
Crossref
Crossref
Scott E. Snyder, Elizabeth R. Butch & Barry L. Shulkin. 2020. Handbook of Radiopharmaceuticals. Handbook of Radiopharmaceuticals
653
701
.
T. V. Shamanskaya, N. A. Andreeva, D. T. Utalieva & D. Yu. Kachanov. (2020) Anti-GD2 immunotherapy with the chimeric antibody ch14.18 for high-risk neuroblastoma. Pediatric Hematology/Oncology and Immunopathology 19:3, pages 173-178.
Crossref
Crossref
Sumeyye Cavdarli, Nao Yamakawa, Charlotte Clarisse, Kazuhiro Aoki, Guillaume Brysbaert, Jean-Marc Le Doussal, Philippe Delannoy, Yann Guérardel & Sophie Groux-Degroote. (2020) Profiling of O-acetylated Gangliosides Expressed in Neuroectoderm Derived Cells. International Journal of Molecular Sciences 21:1, pages 370.
Crossref
Crossref
Francesca del Bufalo & Franco Locatelli. 2020. Neuroblastoma. Neuroblastoma
237
269
.
Chi Zhang, Xilin Xiong, Yang Li, Ke Huang, Ling Liu, Xiaomin Peng & Wenjun Weng. (2019) Cytokine‑induced killer cells/natural killer cells combined with anti‑GD2 monoclonal antibody increase cell death rate in neuroblastoma SK‑N‑SH cells. Oncology Letters.
Crossref
Crossref
Julie Voeller & Paul M. Sondel. (2019) Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology 41:3, pages 163-169.
Crossref
Crossref
Falak Patel & Stefka D. Spassieva. 2018. Sphingolipids in Cancer. Sphingolipids in Cancer
367
388
.
Holger N. Lode. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies
117
139
.
Miho Nakajima & Shakeel Modak. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies
217
242
.
S. M. Chiavenna, J. P. Jaworski & A. Vendrell. (2017) State of the art in anti-cancer mAbs. Journal of Biomedical Science 24:1.
Crossref
Crossref
Shuanglin Han, Olivier Latchoumanin, Guang Wu, Gang Zhou, Lionel Hebbard, Jacob George & Liang Qiao. (2017) Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Letters 390, pages 188-200.
Crossref
Crossref
Hazal Gur, Fatih Ozen, Cemil Can Saylan & Belkis Atasever-Arslan. (2017) Dinutuximab in the Treatment of High-Risk Neuroblastoma in Children. Clinical Medicine Insights: Therapeutics 9, pages 1179559X1771910.
Crossref
Crossref
Jan Müller, Robin Reichel, Sebastian Vogt, Stefan P. Müller, Wolfgang Sauerwein, Wolfgang Brandau, Angelika Eggert & Alexander Schramm. (2016) Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. PLOS ONE 11:10, pages e0163648.
Crossref
Crossref
David M. Barrett & Rochelle Bagatell. (2016) The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma?. Journal of Clinical Oncology 34:21, pages 2437-2439.
Crossref
Crossref
Cady Ploessl, Alice Pan, Kathryn T. Maples & Denise K. Lowe. (2016) Dinutuximab. Annals of Pharmacotherapy 50:5, pages 416-422.
Crossref
Crossref
Dhanya Mullassery & Paul D. Losty. (2016) Neuroblastoma. Paediatrics and Child Health 26:2, pages 68-72.
Crossref
Crossref
Araz Marachelian, Ami Desai, Frank Balis, Howard Katzenstein, Muna Qayed, Michael Armstrong, Kathleen A. Neville, Susan L. Cohn, Mark Bush, Rudy Gunawan, Allison Pecha Lim, Malcolm A. Smith & L. Mary Smith. (2016) Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemotherapy and Pharmacology 77:2, pages 405-412.
Crossref
Crossref
Julie R. Park & Rochelle Bagatell. 2016. Lanzkowsky's Manual of Pediatric Hematology and Oncology. Lanzkowsky's Manual of Pediatric Hematology and Oncology
473
490
.
Yuping Bao, Tianlong Wen, Anna Cristina S. Samia, Amit Khandhar & Kannan M. Krishnan. (2015) Magnetic nanoparticles: material engineering and emerging applications in lithography and biomedicine. Journal of Materials Science 51:1, pages 513-553.
Crossref
Crossref
Ashley ChasickDominic A. SolimandoJrJr & J. Aubrey Waddell. (2015) Dinutuximab and Panobinostat. Hospital Pharmacy 50:9, pages 767-772.
Crossref
Crossref
Wenyong Tong, Mario Maira, Martin Gagnon & H. Uri Saragovi. (2015) Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. PLOS ONE 10:8, pages e0134255.
Crossref
Crossref
S. Groux-Degroote, Y. Guérardel, S. Julien & P. Delannoy. (2015) Gangliosides in breast cancer: New perspectives. Biochemistry (Moscow) 80:7, pages 808-819.
Crossref
Crossref
Essa Mohd Aleassa, Malcolm Xing & Richard Keijzer. (2015) Nanomedicine as an innovative therapeutic strategy for pediatric cancer. Pediatric Surgery International 31:7, pages 611-616.
Crossref
Crossref
Kanwaldeep Mallhi, Lawrence G. Lum, Kirk R. Schultz & Maxim Yankelevich. (2015) Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies. Pediatric Clinics of North America 62:1, pages 257-273.
Crossref
Crossref
Nai-Kong V. Cheung, Irene Y. Cheung, Kim Kramer, Shakeel Modak, Deborah Kuk, Neeta Pandit-Taskar, Elizabeth Chamberlain, Irina Ostrovnaya & Brian H. Kushner. (2014)
Key role for myeloid cells: Phase II results of anti-G
D2
antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma
. International Journal of Cancer 135:9, pages 2199-2205.
Crossref
Crossref
Nikolai Siebert, Diana Seidel, Christin Eger, Madlen Jüttner & Holger N. Lode. (2014) Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody. PLoS ONE 9:9, pages e107692.
Crossref
Crossref
Alejandro Sosnik & Angel M. Carcaboso. (2014) Nanomedicines in the future of pediatric therapy. Advanced Drug Delivery Reviews 73, pages 140-161.
Crossref
Crossref
Nora Berois & Eduardo Osinaga. (2014) Glycobiology of Neuroblastoma: Impact on Tumor Behavior, Prognosis, and Therapeutic Strategies. Frontiers in Oncology 4.
Crossref
Crossref
Mahiuddin Ahmed & Nai-Kong V. Cheung. (2014) Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Letters 588:2, pages 288-297.
Crossref
Crossref
Yaolin Xu, Dana C. Baiu, Jennifer A. Sherwood, Meghan R. McElreath, Ying Qin, Kimberly H. Lackey, Mario Otto & Yuping Bao. (2014) Linker-free conjugation and specific cell targeting of antibody functionalized iron-oxide nanoparticles. Journal of Materials Chemistry B 2:37, pages 6198.
Crossref
Crossref
Nikolai Siebert, Diana Seidel, Christin Eger, Diana Brackrock, Daniel Reker, Manuela Schmidt & Holger N. Lode. (2013) Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. Journal of Immunological Methods 398-399, pages 51-59.
Crossref
Crossref
Emily L. Williams, Stuart N. Dunn, Sonya James, Peter W. Johnson, Mark S. Cragg, Martin J. Glennie & Juliet C. Gray. (2013) Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model. Clinical Cancer Research 19:13, pages 3545-3555.
Crossref
Crossref
Daniel A. Morgenstern, Sylvain Baruchel & Meredith S. Irwin. (2013) Current and Future Strategies for Relapsed Neuroblastoma. Journal of Pediatric Hematology/Oncology 35:5, pages 337-347.
Crossref
Crossref
Holger N. Lode, Manuela Schmidt, Diana Seidel, Nicole Huebener, Diana Brackrock, Matthias Bleeke, Daniel Reker, Sven Brandt, Hans-Peter Mueller, Christiane Helm & Nikolai Siebert. (2013) Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response. Cancer Immunology, Immunotherapy 62:6, pages 999-1010.
Crossref
Crossref
Mahiuddin Ahmed, Yehuda Goldgur, Jian Hu, Hong-Fen Guo & Nai-Kong V. Cheung. (2013) In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors. PLoS ONE 8:5, pages e63359.
Crossref
Crossref
Michael S Magee, Adam E Snook, Glen P Marszalowicz & Scott A Waldman. (2013) Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomarkers in Medicine 7:1, pages 23-35.
Crossref
Crossref
Kerry Parsons, Brooke Bernhardt & Brandy Strickland. (2013) Targeted Immunotherapy for High-Risk Neuroblastoma—The Role of Monoclonal Antibodies. Annals of Pharmacotherapy 47:2, pages 210-218.
Crossref
Crossref
Shakeel Modak, Kim Kramer & Neeta Pandit-Taskar. 2014. Therapeutic Nuclear Medicine. Therapeutic Nuclear Medicine
629
638
.
Maxim Yankelevich, Sri Vidya Kondadasula, Archana Thakur, Steven Buck, Nai‐Kong V. Cheung & Lawrence G. Lum. (2012) Anti‐CD3 × anti‐GD2 bispecific antibody redirects T‐cell cytolytic activity to neuroblastoma targets. Pediatric Blood & Cancer 59:7, pages 1198-1205.
Crossref
Crossref
Amy L. Vāvere, Elizabeth R. Butch, Jason L.J. Dearling, Alan B. Packard, Fariba Navid, Barry L. Shulkin, Raymond C. Barfield & Scott E. Snyder. (2012)
64
Cu-
p
-NH
2
-Bn-DOTA-hu14.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma
. Journal of Nuclear Medicine 53:11, pages 1772-1778.
Crossref
Crossref
Nai-Kong V. CheungIrene Y. CheungBrian H. KushnerIrina OstrovnayaElizabeth ChamberlainKim KramerShakeel Modak. (2012)
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-
Cis
-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
. Journal of Clinical Oncology 30:26, pages 3264-3270.
Crossref
Crossref
Hidenobu Shibuya, Kazunori Hamamura, Hiroshi Hotta, Yasuyuki Matsumoto, Yoshihiro Nishida, Hisashi Hattori, Keiko Furukawa, Minoru Ueda & Koichi Furukawa. (2012)
Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides
GD
2/
GD
3
. Cancer Science 103:9, pages 1656-1664.
Crossref
Crossref
Junichi Hara. (2012) Development of treatment strategies for advanced neuroblastoma. International Journal of Clinical Oncology 17:3, pages 196-203.
Crossref
Crossref
Ruth Esser, Tina Müller, Dörthe Stefes, Stephan Kloess, Diana Seidel, Stephen D. Gillies, Christel Aperlo‐Iffland, James S. Huston, Christoph Uherek, Kurt Schönfeld, Torsten Tonn, Nicole Huebener, Holger N. Lode, Ulrike Koehl & Winfried S. Wels. (2012)
NK cells engineered to express a GD
2
‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin
. Journal of Cellular and Molecular Medicine 16:3, pages 569-581.
Crossref
Crossref
Irene Y. CheungKatharine HsuNai-Kong V. Cheung. (2012) Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology 30:4, pages 426-432.
Crossref
Crossref
L G Durrant, P Noble & I Spendlove. (2012) Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clinical and Experimental Immunology 167:2, pages 206-215.
Crossref
Crossref
Wenyong Tong, Tara Sprules, Kalle Gehring & H. Uri Saragovi. 2012. Rational Drug Design. Rational Drug Design
39
52
.
Corina Flangea, Alina Serb, Eugen Sisu & Alina D. Zamfir. (2011) Reprint of: Chip-based nanoelectrospray mass spectrometry of brain gangliosides. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1811:11, pages 897-917.
Crossref
Crossref
Corina Flangea, Alina Serb, Eugen Sisu & Alina D. Zamfir. (2011) Chip-based nanoelectrospray mass spectrometry of brain gangliosides. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1811:9, pages 513-535.
Crossref
Crossref
Brian H. Kushner, Kim Kramer, Shakeel Modak & Nai-Kong V. Cheung. (2011) High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecan. Pediatric Blood & Cancer 56:3, pages 403-408.
Crossref
Crossref
Ping He, Kim Kramer, Peter Smith-Jones, Pat Zanzonico, John Humm, Steven M. Larson & Nai-Kong V. Cheung. (2010) Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. European Journal of Nuclear Medicine and Molecular Imaging 38:2, pages 334-342.
Crossref
Crossref
Reema Zeineldin. 2007. Nanotechnologies for the Life Sciences. Nanotechnologies for the Life Sciences.
Ching-An Peng & Chung-Hao Wang. (2011) Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation. Cancers 3:1, pages 227-240.
Crossref
Crossref
Alejandra M. Scursoni, Laura Galluzzo, Sandra Camarero, Jessica Lopez, Fabiana Lubieniecki, Claudia Sampor, Valeria I. Segatori, Mariano R. Gabri, Daniel F. Alonso, Guillermo Chantada & María Teresa G. de Dávila. (2011) Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer. Clinical and Developmental Immunology 2011, pages 1-6.
Crossref
Crossref
Brian H. Kushner, Kim Kramer, Shakeel Modak, Karima Yataghene & Nai-Kong V. Cheung. (2011) High-dose cyclophosphamide–irinotecan–vincristine for primary refractory neuroblastoma. European Journal of Cancer 47:1, pages 84-89.
Crossref
Crossref
Philip Lanzkowsky. 2011. Manual of Pediatric Hematology and Oncology. Manual of Pediatric Hematology and Oncology
671
694
.
Victoria Castel, Vanessa Segura & Adela Cañete. (2012) Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clinical and Translational Oncology 12:12, pages 788-793.
Crossref
Crossref
Victoria J. Croog, Kim Kramer, Nai-Kong V. Cheung, Brian H. Kushner, Shakeel Modak, Mark M. Souweidane & Suzanne L. Wolden. (2010) Whole Neuraxis Irradiation to Address Central Nervous System Relapse in High-Risk Neuroblastoma. International Journal of Radiation Oncology*Biology*Physics 78:3, pages 849-854.
Crossref
Crossref
Shakeel Modak & Nai-Kong V. Cheung. (2010) Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treatment Reviews 36:4, pages 307-317.
Crossref
Crossref
Jamal Souady, Denis Dadimov, Stephan Kirsch, Laura Bindila, Jasna Peter-Katalinić & Sergey Y. Vakhrushev. (2010) Software utilities for the interpretation of mass spectrometric data of glycoconjugates: application to glycosphingolipids of human serum. Rapid Communications in Mass Spectrometry 24:7, pages 1039-1048.
Crossref
Crossref
Alan S Wayne, Christian M Capitini & Crystal L Mackall. (2010) Immunotherapy of childhood cancer: from biologic understanding to clinical application. Current Opinion in Pediatrics 22:1, pages 2-11.
Crossref
Crossref
Wenyong Tong, Martin Gagnon, Tara Sprules, Michel Gilbert, Shafinaz Chowdhury, Karen Meerovitch, Karl Hansford, Enrico O. Purisima, John W. Blankenship, Nai-Kong V. Cheung, Kalle Gehring, William D. Lubell & H. Uri Saragovi. (2010) Small-Molecule Ligands of GD2 Ganglioside, Designed from NMR Studies, Exhibit Induced-Fit Binding and Bioactivity. Chemistry & Biology 17:2, pages 183-194.
Crossref
Crossref
Juliet C. Gray & Janice A. Kohler. (2009) Immunotherapy for neuroblastoma: Turning promise into reality. Pediatric Blood & Cancer 53:6, pages 931-940.
Crossref
Crossref
Jian Hu, Xiaodong Huang, Chang-Chun Ling, David R. Bundle & Nai-Kong V. Cheung. (2009) Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody. The Journal of Immunology 183:9, pages 5748-5755.
Crossref
Crossref
Aleksandra Kowalczyk, Małgorzata Gil, Irena Horwacik, Żaneta Odrowąż, Danuta Kozbor & Hanna Rokita. (2009) The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Letters 281:2, pages 171-182.
Crossref
Crossref
J. F. M. Jacobs, P. G. Coulie, C. G. Figdor, G. J. Adema, I. J. M. de Vries & P. M. Hoogerbrugge. (2008) Targets for active immunotherapy against pediatric solid tumors. Cancer Immunology, Immunotherapy 58:6, pages 831-841.
Crossref
Crossref
Lars M. Wagner & Mary K. Danks. (2009) New therapeutic targets for the treatment of high-risk neuroblastoma. Journal of Cellular Biochemistry 107:1, pages 46-57.
Crossref
Crossref
Uta Behrends & Josef Mautner. 2009. Tumor‐Associated Antigens. Tumor‐Associated Antigens
113
141
.
Aurélie Cazet, Sophie Groux-Degroote, Béatrice Teylaert, Kyung-Min Kwon, Sylvain Lehoux, Christian Slomianny, Cheorl-Ho Kim, Xuefen Le Bourhis & Philippe Delannoy. (2009) GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells. Biological Chemistry 390:7.
Crossref
Crossref
Joanne E. Ayriss, Chien-Tsun Kuan, Susan T. Boulton, David A. Reardon & Darell D. Bigner. 2009. CNS Cancer. CNS Cancer
865
898
.
Alberto Garaventa & Giorgio Perilongo. (2008) High risk neuroblastoma: A persistent therapeutic challenge. Pediatric Blood & Cancer 51:6, pages 722-723.
Crossref
Crossref
Reinaldo Almeida, Cristina Mosoarca, Marius Chirita, Valentina Udrescu, Nicolae Dinca, Željka Vukelić, Mark Allen & Alina D. Zamfir. (2008) Coupling of fully automated chip-based electrospray ionization to high-capacity ion trap mass spectrometer for ganglioside analysis. Analytical Biochemistry 378:1, pages 43-52.
Crossref
Crossref
Reinhard Schwartz-Albiez, Simon Laban, Stefan Eichmüller & Michael Kirschfink. (2008) Cytotoxic natural antibodies against human tumours: An option for anti-cancer immunotherapy?. Autoimmunity Reviews 7:6, pages 491-495.
Crossref
Crossref
Cristina Mosoarca, Z̆eljka Vukelić & Alina D. Zamfir. 2008. Applications of Mass Spectrometry in Life Safety. Applications of Mass Spectrometry in Life Safety
71
82
.
Silke Landmeier, Bianca Altvater, Sibylle Pscherer, Bodo R. Eing, Joachim Kuehn, Cliona M. Rooney, Heribert Juergens & Claudia Rossig. (2007) Gene-Engineered Varicella-Zoster Virus–Reactive CD4+ Cytotoxic T Cells Exert Tumor-Specific Effector Function. Cancer Research 67:17, pages 8335-8343.
Crossref
Crossref